Mr. Robin brings to Nektar more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. At Sirna Therapeutics, where he was President and CEO for the past five years, he re-launched the company and created significant shareholder value that led to their acquisition by Merck for $1.1 billion. nektar
Mr. Robin will replace Acting President and CEO Robert Chess who will remain Chairman of the Company. www.nektar.com/wt/page/pr_224647/?ref=ir_archived_press_r...